ERJ Open Research (Oct 2021)

Oximetry neither to prescribe long-term oxygen therapy nor to screen for severe hypoxaemia

  • Yves Lacasse,
  • Sébastien Thériault,
  • Benoît St-Pierre,
  • Sarah Bernard,
  • Frédéric Sériès,
  • Harold Jean Bernatchez,
  • François Maltais

DOI
https://doi.org/10.1183/23120541.00272-2021
Journal volume & issue
Vol. 7, no. 4

Abstract

Read online

Background and objective Transcutaneous pulse oximetry saturation (SpO2) is widely used to diagnose severe hypoxaemia and to prescribe long-term oxygen therapy (LTOT) in COPD. This practice is not based on evidence. The primary objective of this study was to determine the accuracy (false positive and false negative rates) of oximetry for prescribing LTOT or for screening for severe hypoxaemia in patients with COPD. Methods In a cross-sectional study, we correlated arterial oxygen saturation (SaO2) and SpO2 in patients with COPD and moderate hypoxaemia (n=240) and calculated the false positive and false negative rates of SaO2 at the threshold of ≤88% to identify severe hypoxaemia (arterial oxygen tension (PaO2) ≤55 mmHg or PaO2 88% (i.e., false negative result). Conversely, LTOT would be prescribed on the basis of a SaO2 ≤88% in 2% of patients who would not qualify for LTOT (i.e., false positive result). Using a screening threshold of ≤92%, 5% of severely hypoxaemic patients would not be referred for further evaluation. Conclusions Several patients who qualify for LTOT would be denied treatment using a prescription threshold of saturation ≤88% or a screening threshold of ≤92%. Prescription of LTOT should be based on PaO2 measurement.